Skip to content

Oral Vitamin D Supplementation in Elderly Women

Oral Vitamin D Supplementation in Elderly Women: Twice a Day or Three Times a Year? A Randomised Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00575835
Enrollment
40
Registered
2007-12-18
Start date
2006-10-31
Completion date
2007-10-31
Last updated
2008-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Optimal Vitamin D Administration

Keywords

vitamin D, seasonal variation, PTH, bone markers

Brief summary

The aim of this study is to compare oral vitamin D supplementation administered in two different ways, namely either twice a day (800IU/d, 292000IU/y) or three times a year (97333IU every 4 months, 292000IU/y) in elderly women in combination with daily supplementation of calcium 1 gram. We will 1)compare the blood concentrations of 25 OH vitamin D in the two treatment groups amd monitor if a sufficient and safe concentration of 25OH D in blood can be maintained with these two treatments.2) Find out seasonal variation in vitamin D concentrations in these treatments. 3) Find out safety of these treatments

Interventions

DIETARY_SUPPLEMENTvitamin D twice daily

Kalsipos-D, vitamin D3 400 ID/tbl, 2 tbl/day for one year

DIETARY_SUPPLEMENTVitamin D3 oil three times in a year

Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year

Sponsors

Päivikki and Sakari Sohlberg Foundation, Finland
CollaboratorOTHER
Lilly Foundation
CollaboratorUNKNOWN
University of Helsinki
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
70 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Females * 70-80 years * Living in the community

Exclusion criteria

* Renal disease * Diseases that contraindicate vitamin D supplementation * Medications affecting bone * Malignancy

Design outcomes

Primary

MeasureTime frame
Blood 25 OH D vitamin concentrations8 times during the year

Secondary

MeasureTime frame
serum calcium, 24-hour calcium excretion in urine, creatinine clearance8 times during the year

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026